Twist Bioscience Begins Shipping of Synthetic RNA Controls for B.1.351 and P.1 Variants
- U.S. stocks close down on news of Biden tax proposal
- Biden To Propose Capital Gains Tax As High As 43.4% For Wealthy - Bloomberg
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Snap (SNAP) Tops Q1 EPS by 5c, DAUs were 280 million, Offers Guidance
- Credit Suisse (CS) Falls 6% on 'Unacceptable Loss' as Exposure to Archegos Grew to More Than $20 Billion, Set to Raise Over $2 Billion to Support Liquidity
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
-- Additional ‘Assay-Ready’ Controls for B.1.1.7 Now Available --
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping its new synthetic RNA reference controls, which include the new variant strains of SARS-CoV-2 B.1.351 and P.1, that have emerged in South Africa and Brazil, respectively. In addition, Twist began shipping synthetic RNA controls that cover the B.1.1.7 strain of SARS-CoV-2 in a stabilized format that can be shipped and stored at room temperature.
“The launch of the additional controls demonstrates Twist’s continued commitment to the global scientific community as they develop improved tools to identify, monitor and track the evolution of COVID-19,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “The number of vaccinated individuals continues to grow exponentially, providing hope that we are making progress in fighting the pandemic and yet it is critically important that we remain vigilant in surveillance of escape mutations that could cause that trend to reverse.”
For more information on the Twist products to combat COVID-19, please visit: https://www.twistbioscience.com/coronavirus-research-tools.
In March 2020, Twist launched its first synthetic SARS-CoV-2 RNA distinct reference sequences as positive controls for the development of both next-generation sequencing (NGS) and reverse transcription-polymerase chain reaction (RT-PCR) assays to test for SARS-CoV-2. These controls continue to be included in many different assays worldwide and can be used to determine the limit of detection, monitor day-to-day test variations and are included on the U.S. Food and Drug Administration (FDA) website as reference materials for SARS-CoV-2. Twist has subsequently released additional SARS-CoV-2 controls to cover the evolution of the virus and remains committed to using its DNA synthesis platform to offer valuable products that improve health and sustainability.
The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified. For customers interested in alternative variants of SARS-CoV-2, Twist can provide custom controls and offers a suite of research tools, including next-generation sequencing (NGS) products for SARS-CoV-2 as well as a broad respiratory panel and the most comprehensive viral panel.
Customers purchasing synthetic controls are subject to Twist’s leading biosecurity screening protocols and applicable laws and regulations.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation Twist’s ability to deliver synthetic controls for SARS-CoV-2 to its customers, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-K filed with the Securities and Exchange Commission on November 27, 2020 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
SVP, Corporate Affairs
Source: Twist Bioscience Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Hartford (HIG) Reports Q1 EPS of $0.56; Rejects Additional Proposal from Chubb (CB), Raises Buyback
- Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
- AIkido Pharma (AIKI) Announces Withdrawal of S-1 Registration Statement
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!